What is a malignant Brenner tumour of the ovary?
A malignant Brenner tumour is a rare type of ovarian cancer. Its cells look like the lining of the bladder (urothelium), which is why it is also called a transitional-type tumour. It accounts for less than 1% of all ovarian cancers (Koufopoulos et al., 2024).
Brenner tumours come in three forms. Most are benign and are often found by chance during surgery for something else. A smaller number are borderline, meaning they have some abnormal features but do not invade. The malignant form is the rarest, and it usually grows from a pre-existing benign or borderline Brenner tumour (Turashvili and Hanley, 2025).
Malignant Brenner tumours usually affect women after the menopause. They are often large, one-sided tumours that are still confined to the ovary when found. In that situation, the outlook is very good.
How it differs from common ovarian cancer
The most common ovarian cancers are high-grade serous carcinomas, covered with other types on our page on epithelial ovarian cancer. Malignant Brenner tumour behaves quite differently.
| Feature | High-grade serous carcinoma | Malignant Brenner tumour |
|---|---|---|
| Share of ovarian cancers | The majority | Less than 1% |
| Typical stage at diagnosis | Advanced, with spread in the abdomen | More than half at stage I |
| Sides affected | Often both ovaries | Usually one ovary |
| Origin | Usually the fallopian tube | Benign or borderline Brenner tumour |
| Benign component | Absent | Present in the same tumour |
| Outlook | Often guarded | Excellent when confined to the ovary |
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Rare epithelial ovarian cancer with bladder-like (transitional) cells |
| How common | Under 1% of malignant ovarian tumours |
| Typical age | Usually after menopause; median 65 years in a US database |
| Size | Often large; median about 10 cm |
| Sides | Usually one ovary |
| Main treatment | Surgery to remove the tumour and stage the disease |
| Other treatment | Platinum chemotherapy for spread or high risk |
| Outlook | Very good if limited to the ovary; poorer with spread |
2. Types
The Brenner tumour family
| Type | Behaviour | Notes |
|---|---|---|
| Benign Brenner tumour | Harmless | Most common; often small and found by chance |
| Borderline Brenner tumour | Low malignant potential | Abnormal cells without invasion |
| Malignant Brenner tumour | Cancer | Invasive nests of tumour cells next to benign or borderline areas |
What is not a malignant Brenner tumour
In the past, some ovarian cancers that looked transitional but had no benign Brenner component were called “transitional cell carcinoma of the ovary”. Today most of these are classified as a pattern of high-grade serous carcinoma. To be called a malignant Brenner tumour, the cancer must arise next to a benign or borderline Brenner tumour.
3. Causes and risk factors
| Factor | Notes |
|---|---|
| Age | Mainly women in their 50s to 70s |
| Pre-existing Brenner tumour | Thought to be the starting point |
| Walthard nests | Small clusters of bladder-like cells on the tubes and ovaries, possibly the origin of Brenner tumours |
| Mucinous tumours | Brenner tumours often occur together with mucinous cystadenomas |
| Inherited factors | No inherited syndrome is known |
A US hospital review of benign Brenner tumours found Walthard nests close by in most cases and noted their association with mucinous cystadenomas (Alloush et al., 2023). These findings support the idea that Brenner tumours arise from transitional-type cells near the junction of the tube and ovary.
Why do benign tumours sometimes turn malignant?
Experts believe Brenner tumours progress step by step. A benign tumour may gain genetic changes that make it borderline, and further changes may then allow it to invade. Small studies have reported changes in cell-cycle genes such as CDKN2A in some malignant cases. Most benign Brenner tumours, however, never change, so finding one is not a reason for alarm.
4. How does it look
On scans
| Scan | Typical findings |
|---|---|
| Pelvic ultrasound | A large mass, solid or mixed solid and cystic |
| CT | Solid areas, sometimes with chunky calcification |
| MRI | Solid parts often look dark on T2-weighted images because of fibrous tissue |
| CT of chest and abdomen | Checks for spread |
At surgery
| Finding | Description |
|---|---|
| Size | Often more than 10 cm |
| Appearance | Solid and cystic; cut surface may be firm and gritty |
| Sides | Usually one ovary |
| Spread | Absent in most women; when present, often to the pelvis and abdomen |
Under the microscope
| Feature | Description |
|---|---|
| Benign part | Nests of bland bladder-like cells in fibrous tissue |
| Malignant part | Irregular, invading nests or sheets of abnormal transitional or squamous-like cells |
| Stains | GATA3 and p63 often positive; WT1 negative |
| Sampling | The pathologist must examine many areas to find all components |
A careful review stresses that wide sampling and stains are needed so the tumour is not mistaken for other ovarian cancers or for spread from the bladder (Turashvili and Hanley, 2025).
5. Symptoms
Many women have few symptoms until the tumour is large.
Common symptoms
- Swelling or bloating of the abdomen
- Pain or pressure in the pelvis or lower abdomen
- A lump that can be felt in the lower abdomen
- Needing to pass urine more often
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Vaginal bleeding after menopause | Occasionally reported; may reflect hormone activity in the tumour |
| Constipation | Pressure on the bowel |
| Feeling full quickly | Pressure or fluid in the abdomen |
| Fluid in the abdomen (ascites) | More advanced disease |
| Weight loss and tiredness | Advanced disease |
When to seek medical advice
See a doctor if you have persistent bloating, pelvic pain, feeling full quickly or needing to pass urine more often, especially if these occur most days for more than three weeks.
6. Diagnosis
| Step | What is done |
|---|---|
| Examination | Abdominal and pelvic examination |
| Pelvic ultrasound | First test for an ovarian mass |
| CA-125 blood test | May be raised; helps assess risk |
| CT or MRI | Further imaging and staging |
| Surgery | Removal of the mass for diagnosis |
| Pathology | Confirms all components and excludes other cancers |
| Bladder check | Sometimes advised to exclude spread from a bladder cancer |
Why the diagnosis is usually made after surgery
Scans can show that an ovarian mass looks suspicious, but they cannot tell which type of tumour it is. Needle biopsies of ovarian masses are usually avoided when the tumour seems confined to the ovary, because puncturing it could spread cells into the abdomen. The whole tumour is therefore removed, and the final diagnosis comes from the pathology report, typically one to two weeks later.
Staging
Malignant Brenner tumour is staged with the FIGO system for ovarian cancer.
| Stage | Simplified meaning | Share in a US database |
|---|---|---|
| Stage I | Limited to one or both ovaries | About 55% |
| Stage II | Spread within the pelvis | About 14% |
| Stage III | Spread to the abdomen or lymph nodes | About 18% |
| Stage IV | Distant spread | About 12% |
These figures come from a study of 207 women in the US SEER database (Nasioudis et al., 2016).
7. Treatment
Treatment is planned by a gynaecological oncology team. Because the tumour is rare, there are no trials specific to it, and care is based on case series and general ovarian cancer principles.
Surgery
| Procedure | Purpose |
|---|---|
| Removal of the womb, both ovaries and tubes | Standard for most women |
| Removal of the omentum | Checks for hidden spread |
| Washings and peritoneal biopsies | Staging |
| Lymph node removal | Debated; see below |
| Fertility-sparing surgery | Rarely relevant, as most women are past menopause |
| Debulking surgery | Removes as much visible tumour as possible in advanced disease |
Lymph node removal
Studies disagree. In the SEER study, lymph node spread was rare, at about 5%, and removing nodes was not linked to better survival (Nasioudis et al., 2016). A systematic review of 115 published cases found better disease-specific survival in women who had lymph node removal (Koufopoulos et al., 2024). Surgeons weigh these findings for each woman.
Chemotherapy
| Situation | Approach |
|---|---|
| Stage IA, completely removed | Often no chemotherapy |
| Higher-stage or high-risk stage I | Carboplatin and paclitaxel commonly used |
| Recurrence | Further chemotherapy, surgery in selected cases, or clinical trials |
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, wound problems, bowel or bladder changes; early menopause if not yet reached |
| Carboplatin | Low blood counts, tiredness, sickness |
| Paclitaxel | Hair loss, numbness in hands and feet, joint aches |
8. Outlook (prognosis)
| Situation | Five-year disease-specific survival |
|---|---|
| Tumour confined to the ovary | About 95% |
| Spread beyond the ovary | About 51% |
These figures come from Nasioudis et al. (2016). A recent review reported recurrence in nearly half of the published cases with follow-up, and deaths from disease in at least one in five (Turashvili and Hanley, 2025). Published cases may overrepresent difficult tumours, so these numbers should be read with care.
Factors that affect the outlook
| Factor | Effect |
|---|---|
| Stage | The most important factor |
| Ascites | Linked to more recurrences |
| Raised CA-125 | Linked to more recurrences |
| Complete removal | Better outlook |
The systematic review found recurrences more often in women with ascites or raised CA-125 (Koufopoulos et al., 2024).
9. Follow-up
| Period | Typical checks |
|---|---|
| Years 1-2 | Every 3-4 months: symptoms, examination and CA-125 if it was raised |
| Years 3-5 | Every 6 months |
| After 5 years | Yearly or as advised |
Scans are done if symptoms or blood tests suggest a recurrence.
10. Living with a malignant Brenner tumour
- Recover gradually after major surgery, avoiding heavy lifting for several weeks
- Report new bloating, pain or bowel changes
- Ask about menopause symptoms and bone health if surgery caused early menopause
- Keep active and eat a balanced diet
- Seek support from ovarian cancer charities
Life after treatment
Most women with stage I disease return to their usual activities within a few months. Tiredness can last longer, especially after chemotherapy. Gentle exercise, a regular sleep routine and pacing activities through the day all help. Tell your team if low mood, anxiety or fear of recurrence are affecting daily life.
Recovery after surgery
| Period | What to expect |
|---|---|
| First days | Pain control, walking soon after surgery, wound care |
| 2-6 weeks | Gradual return to light activities |
| 6-8 weeks | Most women can drive and return to many normal activities |
| If chemotherapy follows | Usually starts within 4-6 weeks |
Coping with an uncommon diagnosis
Because this cancer is so rare, you may find little information about it online, and some of what you find may refer to other ovarian cancers. Your gynaecological oncology nurse specialist can explain how your situation compares and point you to reliable sources. Ovarian cancer charities offer helplines, support groups and information about life after treatment.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is a Brenner tumour always cancer? | No; most Brenner tumours are benign |
| How was it found? | Often as a large pelvic mass on an ultrasound done for pain, bloating or another reason |
| Is it related to bladder cancer? | No; the cells look similar, but it is a primary ovarian tumour |
| Is it inherited? | No inherited link is known |
| Do I need chemotherapy? | Not always; it depends on stage and other risk factors |
| Will I need my lymph nodes removed? | It depends on your surgeon’s assessment; studies disagree on benefit |
| Can I have hormone replacement therapy? | Often yes; discuss it with your oncologist, as the decision depends on your situation |
| Can it come back? | Yes, especially with advanced disease, so follow-up is important |
12. Questions to ask your care team
- Was the tumour confined to the ovary?
- Did the pathologist find a benign or borderline Brenner component?
- What stage is the cancer?
- Do I need chemotherapy?
- Were my lymph nodes removed, and why?
- How will I be followed up?
- What symptoms should prompt me to call you?
- Is there a specialist nurse I can contact?
- Would a second pathology opinion be useful for such a rare tumour?
Resources
- Alloush, F. et al. (2023) ‘Brenner tumor of the ovary: a 10-year single institution experience and comprehensive review of the literature’, Medical Sciences, 11(1), 18.
- Koufopoulos, N.I. et al. (2024) ‘Malignant Brenner tumor of the ovary: a systematic review of the literature’, Cancers, 16(6), 1106.
- Nasioudis, D. et al. (2016) ‘Malignant Brenner tumors of the ovary; a population-based analysis’, Gynecologic Oncology, 142(1), pp. 44-49.
- Turashvili, G. and Hanley, K. (2025) ‘Malignant Brenner tumor of the ovary: a critical reappraisal’, International Journal of Gynecological Pathology, 44(2), pp. 182-192.
- National Cancer Institute (2026) Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.